Quarterly report · Q1
4483.TEDINET S100P0TK
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.8bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥4.5bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥823m | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥806m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥765m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥538m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥759m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥538m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥63.3bn | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥57.3bn | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥31.9bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥31.4bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥31.4bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥28.3bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥10.1bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥17.9bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥805m | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥909m | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.4bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥13.55 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥9.62 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥12.73 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥9.03 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 49.7% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.4% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥58m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥58m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥90m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥910m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥869m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥41m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥47m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥17m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥439m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥5.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥58m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥35m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥35m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥74m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥782m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥755m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥27m |
| jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥49m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥858m |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.0bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.0bn |
| jpcrp040300-q1r_E35308-000Tele Medicinereportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥330m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥4.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥4.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥35m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 683
| Item | Context | Value | Unit |
|---|---|---|---|
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 兼 ＣＥＯ 松島 陽介 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役副社長 兼 ＣＦＯ 山元 雄太 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役副社長 兼 ＣＦＯ 山元 雄太 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35308 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 44830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Filer name in english | FilingDateInstant | JMDC Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-06-30 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |